PDGFRB and non-small cell lung carcinoma: Nintedanib is an oral triple angiokinase inhibitor targeting the angiogenic pathways mediated by VEGFR1-3, fibroblast growth factor receptors (FGFR) 1–3, and platelet-derived growth factor receptors (PDGFR): nintedanib plus docetaxel have been approved for patients with locally advanced/metastatic NSCLC of adenocarcinoma tumor histology after first-line therapy [8].